In less than a week after inducting Saudi Aramco's chairman Yasir al-Rumayyan in RIL's board, Mukesh Ambani's RIL signs an agreement with Abu Dhabi National Oil Company to make his debut entrance in the Gulf. The deal also signifies the start of RIL's global expansions

Despite uncertainties globally as well as at home, Indian investors are increasingly routing their surplus funds to investing in Bitcoin, Ethereum, and the crypto asset class as a whole.

Billions invested by Silicon Valley giants in Ambani’s RIL to bear fruit soon

Despite official clarifications, press statements, and pull-out promises from controversial projects, the $100-billion Adani group continues to see its shareholders’ confidence eroding.

Control over ‘the message’ on the internet is going to be a key factor in Asia’s growing influence. But its two largest markets, China and India, have two very different ways of achieving that. But in the second of a two-part series, Asia Financial’s Indrajit Basu looks at how democratic India seems just as sensitive to online criticism as its large authoritarian neighbour. New Delhi says it’s protecting the public and cracking down on fake news, the tech giants don’t believe them …

US tech giants' frequent spats with the government could eventually lead to a rethink of their India expansion plans.

Indian government claims Twitter failed to comply with Intermediary Guidelines. Twitter says it is keeping government apprised of steps being taken.

With Asian bourses from Tokyo to Singapore amending their rules to allow the listing of Special Purpose Acquisition Companies (SPACs),...

Fuel demand was hit by the second Covid wave which rocked the country in recent weeks, but is expected to...

Digital currency exchanges are exploring ways to set up in India – lured by rewards far outweighing the perceived risks,...

Three years ago India’s scorching solar energy sector was generating a global buzz, but now a plethora of issues including...

India’s new guidelines for treating Covid has finally dropped the use of controversial Ivermectin, HCQ, and Favipiravir- but they may not disappear from Covid prescriptions just yet, fear some